Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.

about

Long-term statin therapy could be efficacious in reducing the lipoprotein (a) levels in patients with coronary artery disease modified by some traditional risk factors.Management of Statin Intolerance in 2018: Still More Questions Than Answers.

P2860

Q33780263-1E4B09BF-0D57-400B-8B85-C6DE1E90CA16 Q48274059-F6832638-2BFF-4B3D-8A62-8B98652F702D

P2860

Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.

Item

http://www.wikidata.org/entity/Q37636912

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.

@en

type

Item

label

Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.

@en

prefLabel

Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.

@en

P1476

Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.

@en

P2093

Kazuhiko Kotani

http://www.w3.org/2001/XMLSchema#string

P2860

Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor

The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans

Review of clinical practice guidelines for the management of LDL-related risk

The mysteries of lipoprotein(a)

Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor

Lipoprotein (a)-We Know So Much Yet Still Have Much to Learn …

Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)

P304

E78-E82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/JTD.2017.01.40

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Maciej Banach

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28203441

http://www.w3.org/2001/XMLSchema#string

P921

LPA

lipoprotein

P932

5303088

http://www.w3.org/2001/XMLSchema#string

Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.

about

P2860

P2860

Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932